Quantum Leap Healthcare Collaborative Announces the Selection of Sanofi's SAR439859 as the oral SERD Backbone Agent in the Endocrine Optimization Pilot Study of the I-SPY 2 TRIAL for Clinically High Risk, Molecularly Low Risk Stage 2/3 Breast Cancer

By In The News
June 8, 2020 in The Headlines

Recommended Posts

In The News

Posted June 8, 2020

- Share

Posted June 8, 2020

SAN FRANCISCO, June 8, 2020 /PRNewswire/ -- Quantum Leap Healthcare Collaborative™ (Quantum Leap) announced today an evaluation of SAR439859, an oral estrogen receptor degrader (SERD) in a new I-SPY 2 study arm targeting patients with newly diagnosed hormone receptor-positive (HR+)...

View the full article

Link to comment

Share on other sites

Archived

This topic is now archived and is closed to further replies.

Go to topic listing

Most Contributions
1. In The News
  217477
2. Jaydee
  15689
3. Kip Powick
  12014
4. deicer
  11465
5. dagger
  9586
Tell a friend
Love The Airline Website? Tell a friend!
- Email
- Share
Forum Statistics
- Total Topics
  
  267.5k
- Total Posts
  
  553k

Sign In

Quantum Leap Healthcare Collaborative Announces the Selection of Sanofi's SAR439859 as the oral SERD Backbone Agent in the Endocrine Optimization Pilot Study of the I-SPY 2 TRIAL for Clinically High Risk, Molecularly Low Risk Stage 2/3 Breast Cancer

Recommended Posts

In The News

Link to comment

Share on other sites

Archived

Most Contributions

Tell a friend

Forum Statistics

Browse

Activity

Support